Morepen Labs Approves Unaudited Standalone & Consolidated Results for Quarter Ended Sep 30, 2025
Morepen Labs approves unaudited standalone & consolidated financial results for quarter ended September 30, 2025. The board also approved dividend of ₹0.20 per equity share which was already paid on September 22, 2025.
The approval of financial results and dividend payout can have a moderate impact on the company's stock and investor confidence.
The announcement primarily focuses on the approval of financial results, which showcases positive financial performance. The declaration and payment of dividends also contribute to a positive sentiment.
* Approved un-audited standalone & consolidated financial results for quarter and half year ended 30th September 2025. * Consolidated revenue from operations (net) stood at ₹41,157.58 lakhs for the quarter ended September 30, 2025. * Consolidated net profit after minority interest was ₹4,087.46 lakhs for the quarter. * Standalone revenue from operations (net) was ₹36,952.63 lakhs for the quarter ended September 30, 2025. * Standalone net profit was ₹1,437.73 lakhs for the quarter. * Exceptional items include a gain of ₹109.59 lakhs from the sale of equity shares in Dr. Morepen Limited (DML) on July 31, 2025, and a gain of ₹2,472.95 lakhs due to DML ceasing to be a subsidiary. * Shareholders approved a final dividend of ₹0.20 per share in the AGM held on September 6, 2025, which was paid on September 22, 2025. * Dr. Morepen Limited ceased to be a subsidiary w.e.f. 31st July 2025; shareholding reduced to 19.96% from 80%.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.